Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.30 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13720099 | 1.00 | BRD4 (0.33) | BRD4GRIK1GRIK2HDAC1IP6K1 | |
| SCHEMBL14616 | 0.85 | HDAC1 (0.34) | HDAC1 | |
| SCHEMBL13719443 | 0.85 | HDAC1 (0.34) | HDAC1 | |
| SCHEMBL6617 | 0.80 | HDAC1 (0.39) | BRD4GRIK1GRIK2HDAC1 | |
| SCHEMBL13720108 | 0.79 | BRD4 (0.33) | BRD4 | |
| SCHEMBL6954 | 0.79 | BRD4 (0.33) | BRD4 | |
| SCHEMBL14649 | 0.78 | BRD4 (0.35) | BRD4 | |
| SCHEMBL1604526 | 0.75 | HTR2A (0.37) | GRIK1GRIK2HDAC1 | |
| SCHEMBL7450 | 0.75 | HTR2A (0.37) | GRIK1GRIK2HDAC1 | |
| SCHEMBL13701 | 0.72 | BRD4 (0.36) | BRD4GRIK1GRIK2HDAC1IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | BRD4 1128/4885GRIK1 307/4885GRIK2 326/4885 |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | BRD4 1128/4885GRIK1 307/4885GRIK2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.